Glucotrack, Inc. (GCTK)

NASDAQ · Instruments & Medical Devices · Surgical & Medical Instruments & Apparatus

Price
$2.03
Day
-8.56%
Market cap
$21.48M

Close 2026-09-23.

The company

The Company was incorporated on May 18, 2010 under the laws of the State of Delaware. We are a medical device company focused on the development of an implantable continuous blood glucose monitor (“CBGM”) for persons with Type 1 diabetes and Type 2 diabetes using insulin or at risk for hypoglycemia (the “Glucotrack CBGM”). The results on over 1,500 patients demonstrated that patients with diabetes still have the same issues as expressed in 2017 and that interest in a long-term, fully implantable CBGM is high. The Company is developing a long-term CBGM that will allow continuous monitoring of blood glucose levels, which the Company believes is a significant improvement in quality compared to spot finger stick devices and CGM. The Company is currently developing a long-term implantable CBGM with no requirement for an additional wearable component with minimal calibration (the “Glucotrack CBGM”). The Glucotrack CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with effectively zero lag time. In comparison, commercially-available CGM systems measure glucose in the interstitial fluid, which lags behind blood glucose.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings